DNA-binding protein–DNA interface

DNA-binding protein–DNA interfaces are the physical contact regions where regulatory proteins, such as transcription factors, polymerases, and histones, interact with specific genomic DNA sequences to govern cellular processes [Source: Nature Reviews Drug Discovery]. These interfaces are fundamental to the regulation of gene expression, DNA replication, and genome maintenance, making them critical components of cellular homeostasis [Source: Nucleic Acids Research]. In many diseases, particularly cancer, these interfaces are dysregulated, often resulting in the aberrant recruitment of transcription factors to oncogenic promoters [Source: PubMed]. Historically, these sites were viewed as "undruggable" due to their large, relatively flat surface areas that lack the deep pockets typically required for high-affinity small-molecule binding [Source: Science]. Modern therapeutic approaches utilize DNA intercalators, minor groove binders, and synthetic polyamides to disrupt these interactions and modulate gene expression [Source: ACS Chemical Biology]. However, achieving high selectivity remains a significant challenge, as many essential proteins share conserved DNA-binding motifs, leading to potential off-target effects and systemic toxicity [Source: Journal of Medicinal Chemistry].

Other names

Protein-DNA interfaceDNA-protein interaction siteTranscription factor-DNA interfaceDNA-binding domain interface

Drugs targeting these interfaces typically function through DNA intercalation, minor groove binding, or competitive inhibition, which physically prevents the binding of regulatory proteins to their cognate DNA sequences or sterically hinders the progression of transcriptional machinery [Source: Nature Reviews Drug Discovery, PubMed].